Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2023-12-11 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' as per German Securities Trading Act (WpHG). It details the acquisition/disposal of shares with voting rights, crossing a threshold (from 3.17% to 5.33%), and lists the shareholder entities involved. This content directly corresponds to the definition of reporting changes in significant share ownership, which aligns with the 'Major Shareholding Notification' category (MRQ). Although it is a regulatory announcement, MRQ is more specific than the general RNS fallback.
2023-12-11 English
MorphoSys Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Regulatory Filings Classification · 1% confidence The document is a press release dated December 11, 2023, announcing comprehensive results from the Phase 3 MANIFEST-2 study for the drug Pelabresib. It details clinical findings (spleen size reduction, symptom burden, anemia improvement, fibrosis improvement) and safety data. Crucially, it mentions that these findings were presented at the ASH Annual Meeting and that MorphoSys will host an investor event to review the findings, including a webcast. This structure—announcing major clinical data results and immediately scheduling an investor call/event to discuss them—is characteristic of an Earnings Release (ER) or a major data disclosure that often accompanies or precedes an earnings report, but since it is focused purely on clinical trial results and investor presentation logistics, it fits best as an announcement of financial/operational results. However, looking closely at the definitions: 1. It is not a full Annual Report (10-K). 2. It is not a transcript (CT). 3. It is not a standalone Audit Report (AR). 4. It is not a formal Earnings Release (ER) which typically focuses on revenue/net income figures, although it contains operational/clinical results. 5. It is a detailed presentation of study results, which often accompanies or is the core content of an Investor Presentation (IP) or is released alongside an Earnings Release (ER). The text explicitly states: 'MorphoSys will host an investor event to review findings on Monday, December 11' and provides webcast details. This strongly suggests the primary purpose is to disseminate key operational/clinical news to investors, often bundled with earnings news or presented as a standalone investor briefing. Given the depth of the data presentation and the immediate scheduling of an investor event to discuss it, 'Investor Presentation (IP)' is a strong candidate, as the content mirrors what would be in such a presentation. However, the format is a formal 'News Details' press release (EQS-News), which is the standard vehicle for 'Earnings Release (ER)' announcements, even if the content is clinical data rather than pure financial metrics. Since the document details the results and announces the event to discuss them, it functions as the primary disclosure of recent performance/developments. In many contexts, major clinical trial readouts that drive future revenue expectations are classified alongside ERs or as IPs. Given the explicit mention of hosting an 'investor event to review findings,' IP is highly appropriate, but ER is the standard for major corporate news releases announcing period performance/developments. Comparing ER (Initial announcement of periodical financial results) vs IP (Detailed presentation for investors focusing on financials, strategy, and market position): This document is the initial announcement of the MANIFEST-2 results, which are critical to the company's future financial outlook. It is structured as a news release announcing the data and the subsequent investor event. This aligns very closely with the function of an Earnings Release (ER) when clinical data is the primary driver of the period's 'results' for a biotech company, or an Investor Presentation (IP) because it contains the detailed data that will be presented. Since it is a formal press release announcing the results and the follow-up event, ER is often the broader category for such major announcements, but IP captures the nature of the content (detailed study results being presented to investors). Given the detailed breakdown of the Phase 3 trial results, IP is the most precise fit for the *content* being disclosed. Revisiting the structure: It is a press release announcing data presented at a conference and announcing a follow-up investor event. This is often categorized as an Investor Presentation (IP) when the core content is the presentation material itself, or an Earnings Release (ER) if it's tied to a reporting period. Since the focus is entirely on the clinical trial data and the subsequent investor briefing, IP is the best fit.
2023-12-11 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership ('Notification of Major Holdings') pursuant to Article 40, Section 1 of the WpHG (German Securities Trading Act). It details the new and previous percentage of voting rights held by Kynam Global Healthcare Master Fund, LP, crossing a threshold. This directly corresponds to the definition of a major shareholding notification, which in the provided schema maps best to 'Major Shareholding Notification' (MRQ), as it concerns changes in significant share ownership levels crossing thresholds.
2023-12-07 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' under German securities law (WpHG). It specifies the acquisition/disposal of shares with voting rights by T. Rowe Price Group, Inc., and details the resulting percentage changes (from 4.91% to 5.04%). This content directly corresponds to reporting changes in significant share ownership thresholds, which aligns perfectly with the definition for Major Shareholding Notification (MRQ). Although the header mentions 'Voting Rights Announcements', the core content is the change in major holding percentage.
2023-12-07 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in share ownership, voting rights percentages, and details of instruments held by a major shareholder (Bank of America Corporation) in MorphoSys AG, referencing German Securities Trading Act (WpHG) articles. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The code for Major Shareholding Notification is MRQ.
2023-12-07 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting the 'Notification of Major Holdings' pursuant to Article 40 of the WpHG (German Securities Trading Act). It details the acquisition/disposal of shares with voting rights by JPMorgan Chase & Co. and its subsidiaries, crossing specific percentage thresholds (e.g., 10.25% total). This content directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns with the 'Major Shareholding Notification' category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core regulatory content is about major holdings crossing thresholds.
2023-12-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.